Inhibrx Net Income to Non Controlling Interests Trend from 2010 to 2022

INBX -  USA Stock  

USD 23.20  1.79  7.16%

Inhibrx Net Income to Non Controlling Interests yearly trend continues to be fairly stable with very little volatility. Net Income to Non Controlling Interests will likely drop to about 127.1 K in 2022. During the period from 2010 to 2022, Inhibrx Net Income to Non Controlling Interests regression line of anual values had r-squared of 0.39 and arithmetic mean of  139,758. Income Tax Expense is likely to rise to 2,771 in 2022, whereas Consolidated Income is likely to drop (73.9 M) in 2022.

Inhibrx Historical Trends 

 
Refresh
Check Inhibrx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inhibrx main balance sheet or income statement drivers, such as Gross Profit of 14.5 M, Interest Expense of 10 M or Net Income to Non Controlling Interests of 127.1 K, as well as many exotic indicators such as Asset Turnover of 0.14, Book Value per Share of 3.71 or Current Ratio of 5.22. Inhibrx financial statements analysis is a perfect complement when working with Inhibrx Valuation or Volatility modules. It can also supplement various Inhibrx Technical models. Please see the analysis of Inhibrx Correlation against competitors.
All Fundamentals

About Inhibrx Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Inhibrx income statement, its balance sheet, and the statement of cash flows. Inhibrx investors use historical funamental indicators, such as Inhibrx's Net Income to Non Controlling Interests, to determine how well the company is positioned to perform in the future. Although Inhibrx investors may use each financial statement separately, they are all related. The changes in Inhibrx's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Inhibrx's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Inhibrx Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Inhibrx. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Net Income to Non Controlling Interests127.8 K127.1 K
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Inhibrx, Inc. was founded in 2010 and is headquartered in La Jolla, California. Inhibrx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 84 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Inhibrx without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Alpha Finder Now

   

Alpha Finder

Use alpha and beta coefficients to find investment opportunities after accounting for the risk
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Inhibrx using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Inhibrx Correlation against competitors. Note that the Inhibrx information on this page should be used as a complementary analysis to other Inhibrx's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Inhibrx Stock analysis

When running Inhibrx price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Is Inhibrx's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inhibrx. If investors know Inhibrx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inhibrx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Inhibrx is measured differently than its book value, which is the value of Inhibrx that is recorded on the company's balance sheet. Investors also form their own opinion of Inhibrx's value that differs from its market value or its book value, called intrinsic value, which is Inhibrx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inhibrx's market value can be influenced by many factors that don't directly affect Inhibrx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inhibrx's value and its price as these two are different measures arrived at by different means. Investors typically determine Inhibrx value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inhibrx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.